Discovery of S-217622, a Noncovalent Oral SARS-CoV-2 3CL Protease Inhibitor Clinical Candidate for Treating COVID-19
Yuto Unoh, Shota Uehara, Kenji Nakahara, Haruaki Nobori, Yukiko Yamatsu, Shiho Yamamoto, Yuki Maruyama, Yoshiyuki Taoda, Koji Kasamatsu, Takahiro Suto, Kensuke Kouki, Atsufumi Nakahashi, Sho Kawashima, Takao Sanaki, Shinsuke Toba, Kentaro Uemura, Tohru Mizutare, Shigeru Ando, Michihito Sasaki, Yasuko Orba, Hirofumi Sawa, Akihiko Sato, Takafumi Sato, Teruhisa Kato, Yuki Tachibana
Abstract
dose-dependently inhibited intrapulmonary replication of SARS-CoV-2 in mice, indicating that this novel noncovalent inhibitor could be a potential oral agent for treating COVID-19.
Topics & Concepts
PharmacologyProtease inhibitor (pharmacology)PharmacokineticsDosingCoronavirus disease 2019 (COVID-19)In vivoVirtual screeningVirologyDrugCoronavirusEx vivoChemistryPandemicSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Drug discoveryAntiviral drugIn vitroMedicineVirusViral loadDiseaseBiologyInfectious disease (medical specialty)Internal medicineBiochemistryBiotechnologyAntiretroviral therapyComputational Drug Discovery MethodsSARS-CoV-2 and COVID-19 Researchvaccines and immunoinformatics approaches